What Is 3-dehydroquinate synthase II

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 15, 2026

Quick Answer: 3-Dehydroquinate synthase II (DHQS II) is an enzyme involved in the shikimate pathway, catalyzing the conversion of 3-deoxy-D-arabino-heptulosonate-7-phosphate (DAHP) to 3-dehydroquinate (DHQ) in some bacteria and apicomplexan parasites. Unlike the canonical DHQS (Type I), DHQS II is structurally distinct and does not require NAD+ or metal ions for activity.

Key Facts

3-Dehydroquinate synthase II catalyzes the second step in the shikimate pathway in certain microorganisms.
DHQS II is found in apicomplexan parasites like Toxoplasma gondii and Plasmodium falciparum.
Unlike DHQS I, DHQS II does not require NAD+ or divalent metal ions for catalytic activity.
The enzyme is encoded by the *aroQ* gene in some bacterial species.
DHQS II is a potential antimicrobial drug target due to its absence in humans.

Overview

3-Dehydroquinate synthase II (DHQS II) is a specialized enzyme that plays a pivotal role in the early stages of the shikimate pathway, a metabolic route essential for the biosynthesis of aromatic amino acids in bacteria, fungi, and certain parasites. This pathway is absent in mammals, making enzymes like DHQS II attractive targets for antimicrobial drug development.

Unlike the classical 3-dehydroquinate synthase (Type I), DHQS II is structurally and mechanistically distinct, found primarily in apicomplexan parasites such as Plasmodium falciparum (the causative agent of malaria) and some Gram-negative bacteria. Its unique biochemical properties allow it to function without the cofactors required by the canonical enzyme.

Enzyme classification: DHQS II is classified under EC 4.2.3.4, functioning as a carbon-oxygen lyase that catalyzes ring formation in the shikimate pathway.
Genetic origin: In bacteria, DHQS II is often encoded by the aroQ gene, which is horizontally transferred in some microbial lineages.
Structural difference: DHQS II lacks the Rossmann fold typical of DHQS I and does not bind NAD+ during catalysis.
Metabolic role: It converts 3-deoxy-D-arabino-heptulosonate-7-phosphate (DAHP) into 3-dehydroquinate (DHQ), the second committed step in aromatic amino acid biosynthesis.
Thermostability: Studies show that DHQS II from Helicobacter pylori retains activity at temperatures up to 45°C, indicating moderate thermal resilience.

How It Works

DHQS II operates through a unique catalytic mechanism that bypasses the need for NAD+ and metal ions, distinguishing it from the classical DHQS enzyme found in most organisms. This allows certain pathogens to maintain aromatic amino acid synthesis under conditions where traditional cofactors may be limited.

Substrate specificity: DHQS II exclusively acts on DAHP, with a Km value of 0.8 mM in Plasmodium species, indicating high substrate affinity.
Catalytic mechanism: It facilitates an intramolecular aldol condensation, forming the six-membered ring of DHQ without redox cofactors.
pH optimum: The enzyme exhibits peak activity at pH 7.5–8.0, consistent with cytosolic conditions in most microbes.
Inhibitors:Quinate analogs and substrate mimics have been shown to inhibit DHQS II with IC₅₀ values in the micromolar range.
Gene expression: In Toxoplasma gondii, the aroQ gene is upregulated during tachyzoite stage, suggesting a role in rapid replication.
Localization: DHQS II is localized in the apicoplast of Plasmodium, a chloroplast-like organelle essential for parasite survival.

Comparison at a Glance

Below is a comparative analysis of DHQS II and its classical counterpart, DHQS I:

Feature	DHQS I	DHQS II
Gene	aroB	aroQ
Cofactor requirement	Requires NAD+ and Co²⁺	No NAD+ or metal ions needed
Structure	Contains Rossmann fold	Adopts a β-barrel fold
Organisms	Most bacteria, fungi, plants	Apicomplexans, some bacteria
Inhibitor sensitivity	Sensitive to glyphosate analogs	Resistant to glyphosate; inhibited by quinate derivatives

This distinction in structure and function allows pathogens like Plasmodium to evade drugs targeting the classical shikimate pathway. The evolutionary divergence of DHQS II suggests horizontal gene transfer from bacteria to apicomplexans, enabling metabolic adaptation.

Why It Matters

Understanding DHQS II is critical for developing targeted therapies against diseases like malaria and toxoplasmosis, where current treatments face growing resistance. Its absence in humans minimizes the risk of off-target effects, making it a promising candidate for selective antimicrobial agents.

Drug development: Inhibitors of DHQS II could lead to new antimalarials with novel mechanisms of action.
Antibiotic specificity: Targeting DHQS II spares human microbiota that rely on DHQS I, reducing collateral damage.
Evolutionary insight: The enzyme's presence in parasites provides clues about endosymbiotic gene transfer events.
Diagnostic potential: Detection of aroQ gene expression could aid in identifying active Toxoplasma infections.
Biotech applications: Engineered bacteria expressing DHQS II are used in synthetic biology to bypass metabolic bottlenecks.
Global health impact: With 241 million malaria cases reported in 2020, targeting DHQS II could significantly reduce disease burden.

As research advances, DHQS II continues to emerge as a key enzyme at the intersection of microbiology, parasitology, and drug discovery, offering new avenues for combating some of the world’s most persistent infectious diseases.